132-LB: Implications of Initial EGFR Response to Empagliflozin Treatment Effects
INZUCCHI S, KRAUS B, WEIR M, BAKRIS G, MATTHEUS M, CHERNEY D, SATTAR N, HEERSPINK H, RITTER I, EYNATTEN M, ZINMAN B, WANNER C, KOITKA-WEBER A. 132-LB: Implications of Initial EGFR Response to Empagliflozin Treatment Effects. Diabetes 2020, 69 DOI: 10.2337/db20-132-lb.Peer-Reviewed Original ResearchBoehringer Ingelheim-LillyCV deathBoehringer Ingelheim PharmaceuticalsMundipharma InternationalBaseline characteristicsNovo Nordisk A/SJanssen PharmaceuticalsEli LillyRisk reductionEMPA-REG OUTCOMEKDIGO risk categoriesPredictive baseline factorsRenal hemodynamic effectsSerious adverse eventsAdvanced kidney diseaseAdvisory PanelGlomerular filtration rateJanssen Scientific AffairsMultivariate logistic regressionDeath risk reductionNovo NordiskDiuretic therapyEGFR declineSanofi GenzymeCV disease